Aspen's interim results

Johannesburg - JSE listed Aspen (Apn), Africa's largest pharmaceutical
manufacturer, has recorded strong revenue growth for the six months ended 31
December 2008. The positive returns were stimulated by Aspen's recently
expanded international operations. The existing businesses in South Africa
and Australia have once again recorded sustained growth.

* Revenue increased by 91 percent to R4 264 million (R2 230
million).

* Operating profit increased by 84 percent to R1 163 million
(R633.8 million).

* Headline earnings per share (HEPS) increased by 77 percent to
193.8 cents (109.6 cents).

* Increase in earnings per share ("EPS") was lower than HEPS at 54
percent to 192.5 cents (125.0 cents) owing to the inclusion of non-recurring
capital profits in the determination of EPS in the prior year.

Stephen Saad, Aspen Group Chief Executive said "we are pleased to have
delivered such positive results in a challenging operating environment. The
Group's international businesses have been the primary growth driver for the
period under review. For the first time, profits from offshore operations
exceeded those of the South African business. Aspen's local presence remains
strong with increased market share in all pharmaceutical categories. The
Group retaining its ranking as the leading pharmaceutical company in the
South African private and public market sectors."

SOUTH AFRICAN OPERATIONS

Aspen's South African business increased revenue by 32% to R2 331 million
(R1 771 million). This growth was led by the pharmaceutical division which
grew sales by 35% to R1 789 million driven by a substantial increase in
volumes and a positive performance from recently launched products such as
Truvada(tm), Viread(tm), Vectoryl(tm) and Aspen effavirenz. Growth in
earnings before interest, tax and amortisation ("EBITA") was limited to 10%
at R586 million owing to a change in product mix due to a lower margin in
public sector products, higher commodity prices, inflationary pressures and
fixed pricing under both the Single Exit Pricing ("SEP") regulations and the
State Tender awards.

The over-the-counter ("OTC") division delivered good results with leading
brands such as Flusin(tm), Lenadol(r) and Sinuclear(r) contributing
positively. Aspen has successfully launched replacement products under its
major slimming brands Thinz(r), Leanor(tm) and Slenz(r) due to the South
African Medicines Control Council's ("MCC") banning of d-norpseudoephedrine,
the active ingredient in slimming preparations.

Household brands such as Lennon Dutch Medicines(r), Woodwards(tm) Gripewater
and Guronsan(r) C supported the consumer division's 22% revenue growth
which is a pleasing return given the pressure felt in the retail sector.
Laxative brands are being re-developed following the MCC's withdrawal of
phenolphthalein-containing products.

Excellent returns were recorded by Aspen Nutritionals. The existing
portfolio of infant nutritional brands such as Infacare(r), S26(r) and
SMA(r) was enhanced with the launch of Melegi(tm), which is exported to
selected African countries.

High levels of productivity were achieved at Aspen's manufacturing
facilities in order to respond to growing volumes. Continued investment in
manufacturing will unlock additional capacity at the Port Elizabeth site.
Commercialisation of eye-drops at Aspen's Sterile Facility is expected to
take place before year-end. Aspen will supply eye-drops to the USA market
under a contract with Prestige Incorporated.

INTERNATIONAL OPERATIONS

Contributions from Aspen's international operations increased sharply,
following the Group's recent expansion into more than 100 new markets. An
increase in revenue was recorded at R1 934 million (R460 million) while
EBITA rose to R630 million (R101 million). The Group also strengthened its
intellectual property portfolio with the acquisition of Eltroxin(tm),
Lanoxin(tm), Imuran(tm) and Zyloric(tm) from GlaxoSmithKline ("GSK") and
licensing deals with US-based Iroko Pharmaceuticals for the distribution of
products into emerging markets. Revenue from global brands amounted to R696
million.

Aspen Australia recorded sustained growth through the expansion of its
product offering, thereby increasing revenue by 55% to R484 million (R311.7
million).

Group revenue from the Latin American operations comprised 10% with sales of
R408 million. The primary contributor was Brazil's Cellofarm accounting for
R330 million, with the Mexican and Venezuelan companies contributing the
balance. Strategies are in place to grow the Brazilian market share, with
focus being re-directed to the private sector. A brand development strategy
has been initiated and 150 experienced sales representatives have been
recruited for the fulfilment thereof.

Construction of the manufacturing facilities in Campos, Brazil has been
completed. The Brazilian authorities have accredited the Penem Facility
thereby enabling the commencement of commercial production. The Penicillin
Facility is awaiting final regulatory approval.

Shelys, the Group's business in East Africa, recorded revenue of R200
million in Tanzania, Kenya and Uganda. The OTC Manufacturing Facility under
construction in Nairobi, is due for completion before the end of 2009.

PROSPECTS

Growth in South African volumes is expected to remain buoyant during the
second half of the year. The 13.2% increase in SEP will offset the impact of
higher supply costs. Despite trading difficulties in the retail sector, it
is anticipated that the successful strategies implemented by the consumer
division will yield favourable results.

Additional production capacity will be realised during the forthcoming
calendar year when Aspen's three major capital projects in Port Elizabeth,
valued at R1 billion, are completed. The solid dosage manufacturing and
packing capabilities will cater for anticipated growth in demand from
domestic and international markets. The Sterile Facility will provide Aspen
with production capabilities in injectables, hormonal injectables and
eye-drops for all major international markets.

It is expected that the international businesses will provide significant
impetus to the Group's growth. Cognisance should be taken of influencing
factors most notably global currency exposures and world market volatility.
The product pipeline for the international business remains a major focus
area with benefits expected to become apparent in the next two to three
years. The Bangalore Oncology Facility has been accredited by the Australian
Therapeutic Goods Association and commercial production is scheduled to
commence in 2010.

The disposal of Aspen's 50% shareholding in Astrix remains subject to
fulfilment of conditions precedent.

Aspen's performance in the first half of this financial year has shown
resilience and strategies have been implemented which are designed to add to
the Group's performance in future years.